DCA and Avemar Show Clinical Promise Against Hormone Resistant Prostate Cancer

June 15, 2012 - PRLog -- As a follow up to a previous reports of DCA and Avemar working against AML Leukemia and CLL Leukemia, a new case has surfaced of the protocol working against Hormone Resistant Prostate Cancer:

   "Hormone refractory [(resistant)] prostate cancer is cancer that has become resistant to the effects of hormone therapy. Hormone therapy is used to treat prostate cancer in some men, but it often will only work for a limited amount of time before the cancer is said to have become refractory (resistant)."

   –  http://prostatecancer.about.com/od/importantdefinition1/g/What-Is-Hormone-Refractory-Prostate-Cancer.htm

   "DCA + Avemar resulted in a PSA drop of about 25% in just 2 weeks!"

   – Dr. Akbar Khan, Medicor Cancer Centres

PSA is Prostate-specific antigen.  It is a marker for the severity of prostate cancer.

   "PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders."

   – http://en.wikipedia.org/wiki/Prostate-specific_antigen

Here is a link to the case study involving CLL Leukemia:

http://www.martincwiner.com/dca-and-avemar-show-clinical-...

Here is a link to the case study involving AML Leukemia:

http://www.martincwiner.com/dca-and-avemar-show-clinical-promise-against-aml-leukemia/

And here is a link to the original video discussing the protocol:

http://www.martincwiner.com/dca-and-avemar-a-theoretical-protocol-for-cancer/